SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Unquoted Biotechs
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Ian@SI who wrote (234)6/8/2010 2:35:50 PM
From: scaram(o)uche   of 253
 
Yes. Correct.

I've been tongue-in-cheek suggesting, for several years, that someone develop a 2A/2B antagonist to co-formulate with stuff like fenfluramine. Can find the links, if you're interested in the contexts.

Never thought to actually treat (rather than prophylax for) PAH..... seems like an expensive and risky trial process.... not a good first indication for a biotech, partnered project or not?

And, long after joking around about the co-formulation bit, I found MY VERY OWN first application, claim 3.....

Message 25995483

;-)
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News